114 related articles for article (PubMed ID: 24256491)
1. Rituximab synergizes with hydroxyurea or vincristine in the killing of Ramos Burkitt's lymphoma B cell line.
Deyab M; Elbanani A; Tabal S; Geriani H; Lamami Y; Bredan A; Abulayha A
Cancer Biother Radiopharm; 2014 Mar; 29(2):87-90. PubMed ID: 24256491
[TBL] [Abstract][Full Text] [Related]
2. Rituximab increases the cytotoxicities of vincristine and hydroxyurea through caspase-dependent and caspase-independent cell death, respectively.
Tabal S; Elbanani A; Deyab M; Abulayha A
Cancer Biother Radiopharm; 2015 Apr; 30(3):125-31. PubMed ID: 25714921
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea potentiates the caspase-independent killing of B-cell lines by rituximab and GA101.
Daniels I; Abulayha A; Haynes AP
Oncol Res; 2012; 20(12):545-55. PubMed ID: 24139412
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
[TBL] [Abstract][Full Text] [Related]
5. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
6. Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab.
Barboza NM; Medina DJ; Budak-Alpdogan T; Aracil M; Jimeno JM; Bertino JR; Banerjee D
Cancer Biol Ther; 2012 Jan; 13(2):114-22. PubMed ID: 22336911
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
Sun XF; Zhen ZJ; Liu DG; Xia Y; Xiang XJ; Chen XQ; Ling JY; Zheng L; Luo WB; Lin H; He YJ; Guan ZZ
Ai Zheng; 2007 Dec; 26(12):1339-43. PubMed ID: 18076797
[TBL] [Abstract][Full Text] [Related]
8. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis may be either suppressed or enhanced with strategic combinations of antineoplastic drugs or anti-IgM.
Lin CK; Nguyen TT; Morgan TL; Mei RL; Kaptein JS; Kalunta CI; Yen CF; Park E; Zou HY; Lad PM
Exp Cell Res; 1998 Oct; 244(1):1-13. PubMed ID: 9770343
[TBL] [Abstract][Full Text] [Related]
10. TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20.
Kawabata KC; Ehata S; Komuro A; Takeuchi K; Miyazono K
Oncogene; 2013 Apr; 32(16):2096-106. PubMed ID: 22665052
[TBL] [Abstract][Full Text] [Related]
11. Sustained complete remission following a combination of very low intensity chemotherapy with rituximab in an elderly patient with Burkitt's lymphoma.
Cohen Y; Amir G; Rachmilewitz EA; Polliack A
Haematologica; 2002 Jan; 87(1):ELT04. PubMed ID: 11801488
[No Abstract] [Full Text] [Related]
12. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
13. Conventional dose intensive immunochemotherapy regimen in an adult patient with very late relapse of Burkitt's lymphoma.
Italiano A; Peyrade F; Soler C; Cardot N; Thyss A
J Chemother; 2007 Apr; 19(2):236-8. PubMed ID: 17434838
[No Abstract] [Full Text] [Related]
14. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
Shi W; Han X; Yao J; Yang J; Shi Y
Leuk Res; 2012 Jun; 36(6):749-55. PubMed ID: 22475365
[TBL] [Abstract][Full Text] [Related]
15. Durable remission induced by rituximab-containing chemotherapy in a patient with primary refractory Burkitt's lymphoma.
Yokohama A; Tsukamoto N; Uchiumi H; Handa H; Matsushima T; Karasawa M; Murakami H; Nojima Y
Ann Hematol; 2004 Feb; 83(2):120-3. PubMed ID: 14513289
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of Burkitt lymphoma and Burkitt-like lymphoma].
Maruyama D
Rinsho Ketsueki; 2011 Oct; 52(10):1645-54. PubMed ID: 21971242
[No Abstract] [Full Text] [Related]
17. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
18. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma.
Pohlen M; Gerth HU; Liersch R; Koschmieder S; Mesters RM; Kessler T; Appelmann I; Müller-Tidow C; Berdel WE
Am J Hematol; 2011 Dec; 86(12):E61-4. PubMed ID: 21898532
[TBL] [Abstract][Full Text] [Related]
20. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
Schmitz N; Nickelsen M; Ziepert M; Haenel M; Borchmann P; Schmidt C; Viardot A; Bentz M; Peter N; Ehninger G; Doelken G; Ruebe C; Truemper L; Rosenwald A; Pfreundschuh M; Loeffler M; Glass B;
Lancet Oncol; 2012 Dec; 13(12):1250-9. PubMed ID: 23168367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
